Governments Who Support Transparency Must Raise Their Voice at the World Health Assembly

Joint Statement | 17 May 2019 | Download PDF

Health Action International (HAI) was joined today by 13 other civil society organisations in calling for governments to show their support for higher standards of transparency as a means to improve access to medicines. The joint statement read:

We, health advocates,

Sexual and Reproductive Health Commodities: Four-country Comparison 2019

Report | 17 May 2019 | Download PDF

This latest report from Health Action International (HAI) presents the results of surveys of the price, availability and affordability of sexual and reproductive health commodities (SRHC) in Kenya, Tanzania, Uganda and Zambia. The surveys were  carried out by HAI and in-country partners (Medicines Transparency Alliance [MeTA] Kenya,

Clinical Trials at European Universities: Mapping Unreported Drug Trials

Joint Report | 1 May 2019 | Download PDF

Failure to report clinical trial results is not a victimless crime. It has substantial negative consequences for patients and public health.

Since July 2014, European Union rules have required each and every clinical trial registered on  the EU clinical trials registry to post summary results onto the registry within 12 months of trial completion (6 months for paediatric trials).

HAI Welcomes European Parliament Backing of SPC Manufacturing Waiver

Statement | 17 April 2019 | Download PDF

Following the European Parliament’s approval of a Supplementary Protection Certificate (SPC) manufacturing waiver for export, Jaume Vidal, Policy Advisor with Health Action International (HAI) made the following statement:

‘Today’s European Parliament approval—by a huge majority—of the SPC manufacturing waiver for export almost completes the consultation process started by the European Commission in May last year.

WHO Member States Must Grasp Opportunity to Improve Medicines Price Transparency

Press Release | 11 April | Download PDF

World Health Assembly Resolution Can Set the Right Course for Governments and Patients

JOHANNESBURG—At a side-event during the World Health Organization’s (WHO) 2nd Fair Pricing Forum in South Africa today, civil society groups and public health experts sent an urgent message to WHO Member States to tackle high medicines prices and support a proposed World Health Assembly (WHA) resolution to improve price transparency.

Improving Access to Medicines in the EU: A Guide to HAI’s European Projects 2019

Brochure | 28 March 2019 | Download PDF

Medicines are crucial not only for improving our health and well-being, but also to fulfil our human right to health. But in the European Union (EU), the price of many new patented medicines is growing higher every year, jeopardising the ability of patients to access them when needed and threatening the sustainability of our healthcare systems.

Antimicrobial Resistance Coalition Response to Public Consultation

Consultation Response | 20 February, 2019 | Download PDF

Health Action International joined 15 other civil society organisations, as part of the Antimicrobial Resistance Coalition (ARC), in response to a World Health Organization (WHO) public consultation on the draft recommendations of the Interagency Coordination Group on Antimicrobial Resistance (IACG).

ARC urges the IACG to communicate to policymakers reading its final recommendations that:

  • The need to respond to the challenge of antimicrobial resistance is urgent
  • Resources–both financial and technical–must be commensurate with the call for action on AMR.

Clinical Trials in the European Union: A Roadmap to Greater Transparency

Report | 6 February, 2019 | Download PDF

Clinical trials are at the core of the pharmaceutical research and development process. The results of these studies inform decision-making on market approval, medicines pricing and reimbursement, and clinical practice. Clinical trial transparency is therefore extremely important for policy makers, public health bodies,